Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Raderer

Showing results (211-220 of 264) with videos related to

Pageof 27
Sort By:
JACC. Advances|August 1, 2025
Prognostic Value of Biomarkers in Cancer Patients Treated With Immune Checkpoint Inhibitor TherapyChristopher Mann, Ulrike Pailer, Andreas Spannbauer, et al.
Theranostics|January 4, 2021
CXCR4 PET imaging of mantle cell lymphoma using [<sup>68</sup>Ga]Pentixafor: comparison with [<sup>18</sup>F]FDG-PETMarius E Mayerhoefer, Markus Raderer, Wolfgang Lamm, et al.
Haematologica|April 21, 2018
Novel <i>GPR34</i> and <i>CCR6</i> mutation and distinct genetic profiles in MALT lymphomas of different sitesSarah Moody, Joe Sneath Thompson, Shih-Sung Chuang, et al.
Leukemia & Lymphoma|January 31, 2008
Prognostic value of T-cell receptor gamma rearrangement in peripheral blood or bone marrow of patients with peripheral T-cell lymphomasChristian Schützinger, Harald Esterbauer, Gregor Hron, et al.
The Lancet. Oncology|October 24, 2018
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 studyTadeusz Robak, Jie Jin, Halyna Pylypenko, et al.
Haematologica|April 19, 2012
Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical responseUlrich Jäger, Michael Fridrik, Markus Zeitlinger, et al.
Cancer Medicine|May 31, 2024
Prevalence and biopsychosocial indicators of fatigue in cancer patientsElisabeth L Zeilinger, Irina Zrnic-Novakovic, Claudia Oppenauer, et al.
Frontiers in Cardiovascular Medicine|November 8, 2021
Inflammation-Based Scores as a Common Tool for Prognostic Assessment in Heart Failure or CancerHenrike Arfsten, Anna Cho, Suriya Prausmüller, et al.
Clinical Nuclear Medicine|September 25, 2015
Does Delayed-Time-Point Imaging Improve 18F-FDG-PET in Patients With MALT Lymphoma?: Observations in a Series of 13 PatientsMarius E Mayerhoefer, Chiara Giraudo, Daniela Senn, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 9, 2023
Chemokine receptor-targeted PET/CT provides superior diagnostic performance in newly diagnosed marginal zone lymphoma patients: a head-to-head comparison with [<sup>18</sup>F]FDGAleksander Kosmala, Johannes Duell, Simone Schneid, et al.
Pageof 27

Showing results (211-220 of 264) with videos related to

Sort By:
Pageof 27
JACC. Advances|August 1, 2025
Prognostic Value of Biomarkers in Cancer Patients Treated With Immune Checkpoint Inhibitor TherapyChristopher Mann, Ulrike Pailer, Andreas Spannbauer, et al.
Theranostics|January 4, 2021
CXCR4 PET imaging of mantle cell lymphoma using [<sup>68</sup>Ga]Pentixafor: comparison with [<sup>18</sup>F]FDG-PETMarius E Mayerhoefer, Markus Raderer, Wolfgang Lamm, et al.
Haematologica|April 21, 2018
Novel <i>GPR34</i> and <i>CCR6</i> mutation and distinct genetic profiles in MALT lymphomas of different sitesSarah Moody, Joe Sneath Thompson, Shih-Sung Chuang, et al.
Leukemia & Lymphoma|January 31, 2008
Prognostic value of T-cell receptor gamma rearrangement in peripheral blood or bone marrow of patients with peripheral T-cell lymphomasChristian Schützinger, Harald Esterbauer, Gregor Hron, et al.
The Lancet. Oncology|October 24, 2018
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 studyTadeusz Robak, Jie Jin, Halyna Pylypenko, et al.
Haematologica|April 19, 2012
Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical responseUlrich Jäger, Michael Fridrik, Markus Zeitlinger, et al.
Cancer Medicine|May 31, 2024
Prevalence and biopsychosocial indicators of fatigue in cancer patientsElisabeth L Zeilinger, Irina Zrnic-Novakovic, Claudia Oppenauer, et al.
Frontiers in Cardiovascular Medicine|November 8, 2021
Inflammation-Based Scores as a Common Tool for Prognostic Assessment in Heart Failure or CancerHenrike Arfsten, Anna Cho, Suriya Prausmüller, et al.
Clinical Nuclear Medicine|September 25, 2015
Does Delayed-Time-Point Imaging Improve 18F-FDG-PET in Patients With MALT Lymphoma?: Observations in a Series of 13 PatientsMarius E Mayerhoefer, Chiara Giraudo, Daniela Senn, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 9, 2023
Chemokine receptor-targeted PET/CT provides superior diagnostic performance in newly diagnosed marginal zone lymphoma patients: a head-to-head comparison with [<sup>18</sup>F]FDGAleksander Kosmala, Johannes Duell, Simone Schneid, et al.
Pageof 27